Archives
Can Endogenous Milk Promoters Improve Rabbit Pharming?
2026-11-12
A 2025 study examined whether targeted insertion of a reporter gene into the rabbit CSN2 milk-protein locus could raise recombinant protein output. The resulting line transmitted the edited allele and produced 15–20 g/L tdTomato in milk from two homozygous females. The finding is technically important but remains bounded by the reporter-based model, small expression cohort, and lack of a matched therapeutic-protein comparison.
Why the CSN2 Locus Raised Rabbit Milk Yield
2026-11-12
A 2025 study reported that placing a fluorescent reporter under the endogenous CSN2 milk-protein regulatory environment produced 15–20 g/L in milk from homozygous rabbits. The result supports locus-targeted expression as a promising animal-pharming strategy, while leaving major questions about generality, product quality, animal-to-animal variation, and performance with therapeutic proteins.
What the LNP Review Shows About p53 mRNA
2026-11-11
A critical reading of a 2025 review finds that lipid nanoparticles provide a plausible delivery framework for p53-encoding mRNA, but the p53-specific evidence remains secondary, preclinical and formulation-dependent. The review supports a mechanistic rationale for improving intracellular delivery while leaving the size, durability and clinical relevance of antitumor effects uncertain.
Endogenous Promoters and Rabbit Pharming Yield
2026-11-11
A targeted rabbit line expressing tdTomato from the endogenous CSN2 locus produced a reported 15–20 g/L in milk from two homozygous females. The result supports a promising expression strategy, but it does not yet establish comparable performance for therapeutic proteins, total production, product quality, or industrial scalability.
Why CSN2 Targeting Raises Rabbit Pharming Yield
2026-11-10
A 2025 study links targeted insertion at the rabbit CSN2 locus with recombinant-protein concentrations of 15–20 g/L in milk from two homozygous females. The result supports a mechanistic role for endogenous mammary regulation, while leaving unresolved how much of the improvement derives from promoter activity, locus control, allele dosage, or properties specific to the tdTomato reporter.
Why CSN2 Targeting Raises Rabbit Pharming Yield
2026-11-10
A recent rabbit study tested whether placing a recombinant reporter gene at the endogenous CSN2 milk-protein locus could overcome the variability of conventional transgenesis. The reported 15–20 g/L milk concentration is striking, but its interpretation is limited by the reporter choice, small number of high-producing animals, and lack of a matched conventional control.
Can Targeted Rabbit Pharming Raise Protein Yield?
2026-11-09
A 2025 study reports unusually high milk concentrations of a reporter protein from rabbits carrying a targeted insertion at the endogenous CSN2 locus. The result supports a promising expression strategy, but its generalizability to therapeutic proteins and industrial production remains uncertain.
Targeted Expression in Rabbit Pharming
2026-11-09
A 2025 study linked a recombinant reporter gene to the rabbit CSN2 milk-protein locus and reported substantially higher milk concentrations than historical conventional-transgenic examples. The result supports locus-aware expression as a promising research strategy, but the evidence remains specific to one reporter, one rabbit line, and a concentration-based readout.
Calcium-Lactate Nanomedicine in Colorectal Cancer
2026-11-08
The cited study presents a calcium-lactate nanoparticle that combines bufalin delivery with CD47-targeting CRISPR/Cas9 to link tumor-cell stress, macrophage reprogramming, and antitumor immunity. This editorial separates the study’s preclinical nanomedicine findings from the analytical role of an associated high-fidelity PCR reagent and examines the evidence limits around pyroptosis, gene editing, metastasis control, and translation.
What the High-Yield Rabbit Pharming Study Shows
2026-11-07
A 2025 study reported unusually high milk concentrations of a fluorescent reporter after targeted insertion at the rabbit CSN2 locus. The result supports a compelling biological hypothesis about endogenous mammary-gland regulation, but its small animal-level dataset and reporter-based design limit how confidently it can be generalized to therapeutic proteins or industrial production.
What High-Yield Rabbit Pharming Data Really Show
2026-11-06
A 2025 study links targeted insertion at the rabbit CSN2 locus with markedly higher reporter-protein levels in milk, but the evidence remains a proof of biological feasibility rather than validation of a therapeutic manufacturing platform.
When Context Changes p53 mRNA Results
2026-11-06
A p53 mRNA result can reflect cargo expression, nanoparticle trafficking, immune activation, combination treatment, or tumor biology. This editorial separates those causal layers and explains why findings from different models, formulations, comparators, and readouts should not be treated as interchangeable evidence.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-05
A targeted rabbit line produced substantially more recombinant reporter protein in milk than historical conventional-transgenic benchmarks, but the comparison is not yet a definitive test of therapeutic manufacturing performance. The key uncertainties concern construct-specific biology, limited animal replication, product quality, and whether the yield advantage generalizes across proteins.
CSN2-Directed Expression in Rabbit Pharming
2026-11-05
A 2025 study tested whether targeted placement of a reporter gene at the rabbit CSN2 milk-protein locus could improve recombinant protein output. The reported 15–20 g/L range is notable, but its generalizability remains limited by the reporter construct, the small number of high-producing animals, and the absence of a matched conventional-transgenic control.
How CSN2 Knock-In Raised Rabbit Pharming Yield
2026-11-04
A 2025 study tested whether placing a reporter transgene at the rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenic lines. The resulting homozygous animals produced reported tdTomato concentrations of 15–20 g/L in milk, but the evidence remains an early proof of principle because it rests on a small number of animals and a fluorescent reporter rather than a therapeutic protein.